Education
About Us
Working with TipRanks
Follow Us
Pacira (PCRX)
:PCRX
RESEARCH TOOLSreports
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.61Last Year’s EPS
0.62Same Quarter Last Year
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -7.29%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
Pacira BioSciences reported strong financial performance for 2024 with record revenues and significant reimbursement progress for its flagship product, EXPAREL. However, the delayed uptake of the No Pain Act reimbursement and increased operating expenses are challenges that the company needs to navigate. The strategic acquisition of GQ Bio and expansion of commercial coverage are notable steps forward.Company Guidance
During the Pacira BioSciences Fourth Quarter 2024 conference call, the company provided guidance for 2025, projecting total revenue between $725 million and $765 million. They anticipate volume-driven growth, with a focus on their flagship product, EXPAREL, which benefits from the NOPAIN Act's reimbursement pathway for 18 million outpatient surgical procedures. The company expects a double-digit compound annual growth rate in product revenues over the next five years and plans for a 5-percentage point expansion in gross margin from 2024 levels. Additionally, Pacira aims to advance its innovative pipeline by establishing five novel programs and forming at least five clinical or commercial partnerships by 2030. The company is also investing in targeted direct-to-consumer marketing to drive patient demand and expand product utilization.Record Revenues Achieved
Pacira BioSciences delivered record revenues of $701 million in 2024, reaching the high end of their guided range.
EXPAREL Reimbursement Milestone
EXPAREL received its own product-specific J code with a reimbursement rate of average selling price plus 6%, enhancing patient access and reimbursement processes.
Commercial Coverage Expansion
Commercial payers now cover roughly 40 million lives, doubling previous coverage, with TRICARE also on board.
Strategic Acquisition of GQ Bio
Pacira acquired the remaining ownership stake in GQ Bio, adding a high-capacity local delivery platform for genetic medicines.
Strong Product Portfolio Performance
All three product lines—EXPAREL, ZILRETTA, and iovera—showed sales increases, with ZILRETTA achieving $33.1 million in sales, up from $28.7 million in 2023.
---
PCRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PCRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $25.38 | $24.05 | -5.24% |
| Nov 06, 2024 | $17.67 | $17.70 | +0.17% |
| Jul 30, 2024 | $19.54 | $20.65 | +5.68% |
| May 07, 2024 | $26.51 | $29.65 | +11.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pacira (PCRX) report earnings?
Pacira (PCRX) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Pacira (PCRX) earnings time?
Pacira (PCRX) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PCRX EPS forecast?
PCRX EPS forecast for the fiscal quarter 2025 (Q1) is 0.61.
---